Physician profile
John Ruffini
NPI 1265543227
$1,699.33
in general payments reported to CMS, 2019-2025
22 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $86.18 · 2021: $206 · 2022: $326 · 2023: $166 · 2024: $299 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $302.59 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $204.51 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.61 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $128.28 | 2024-2025 | Xdemvy |
| Abbvie INC. | $112.30 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $103.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.30 | 2019-2023 | |
| Harrow Eye, LLC | $79.19 | 2024-2025 | Vevye |
| Amgen INC. | $67.88 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $62.97 | 2023-2024 | Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $55.37 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $49.45 | 2022-2024 | Oxervate |
| Biotissue Holdings INC. | $45.22 | 2020-2023 | |
| Eyevance Pharmaceuticals LLC | $38.88 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $36.77 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $36.04 | 2019 | |
| Aerie Pharmaceuticals, INC. | $30.39 | 2021 | |
| Horizon Therapeutics Plc | $30.29 | 2021 | |
| Allergan, INC. | $23.95 | 2021 | |
| Thea Pharma INC. | $23.15 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.22 | 2021 | |
| Akorn, INC. | $16.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ruffini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.